A recent report from CPhI Japan has forecast that this year, 2018, will be a transformative year for Japanese pharma as the market is expected to see growth in generics, biosimilars and internationalisation.
Japan
The CPhI Japan 2018 report identifies demographic pressures on healthcare costs as a driver for political agenda that should benefit those companies with lower cost solutions. As such, generics and, particularly for the innovative Japanese pharma industry, biosimilars are expected to experience rapid growth.